Therefore, evaluating diagnostic usefulness as a biomarker, targeting the c-KIT and VEGFR pathways can possibly provide a potentially fit targeted tumor therapeutic modality against kidney cancer or renal cell carcinoma. This evidence concerns the gene KIT and kidney cancer.